Cargando…

Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness

BACKGROUND: Exclusion criteria that are treatment effect modifiers (TEM) decrease RCTs results generalisability and the potentials of effectiveness estimation. In “augmented RCTs”, a small proportion of otherwise-excluded patients are included to allow for effectiveness estimation. In Hodgkin Lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordon, Clementine, Sanchez, Benoit, Zhang, Mei, Wang, Xiaowei, Hunt, Phillip, Belger, Mark, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313858/
https://www.ncbi.nlm.nih.gov/pubmed/37397428
http://dx.doi.org/10.1016/j.conctc.2023.101142
_version_ 1785067196430417920
author Nordon, Clementine
Sanchez, Benoit
Zhang, Mei
Wang, Xiaowei
Hunt, Phillip
Belger, Mark
Karcher, Helene
author_facet Nordon, Clementine
Sanchez, Benoit
Zhang, Mei
Wang, Xiaowei
Hunt, Phillip
Belger, Mark
Karcher, Helene
author_sort Nordon, Clementine
collection PubMed
description BACKGROUND: Exclusion criteria that are treatment effect modifiers (TEM) decrease RCTs results generalisability and the potentials of effectiveness estimation. In “augmented RCTs”, a small proportion of otherwise-excluded patients are included to allow for effectiveness estimation. In Hodgkin Lymphoma (HL) RCTs, older age and comorbidity are common exclusion criteria, while also TEM. We simulated HL RCTs augmented with age or comorbidity, and explored in each scenario the impact of augmentation on effectiveness estimation accuracy. METHODS: Simulated data with a population of HL individuals initiating drug A or B was generated. There were drug-age and drug-comorbidity interactions in the simulated data, with a greater magnitude of the former compared to the latter. Multiple augmented RCTs were simulated by randomly selecting patients with increasing proportions of older, or comorbid patients. Treatment effect size was expressed using the between-group Restricted Mean Survival Time (RMST) difference at 3 years. For each augmentation proportion, a model estimating the “real-world” treatment effect (effectiveness) was fitted and the estimation error measured (Root Mean Square Error, RMSE). RESULTS: In simulated RCTs including none (0%), or the real-world proportion (30%) of older patients, the interquartile range of RMST difference was 0.4–0.5 years and 0.2–0.3 years, respectively, and RMSE were 0.198 years (highest possible error) and 0.056 years (lowest), respectively. Augmenting RCTs with 5% older patients decreased estimation error substantially (RMSE = 0.076 years). Augmentation with comorbid patients proved less useful for effectiveness estimation. CONCLUSION: In augmented RCTs aiming to inform the effectiveness of drugs, augmentation should concern in priority those exclusion criteria of suspected important TEM magnitude, so as to minimie the proportion of augmentation necessary for good effectiveness estimations.
format Online
Article
Text
id pubmed-10313858
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103138582023-07-02 Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness Nordon, Clementine Sanchez, Benoit Zhang, Mei Wang, Xiaowei Hunt, Phillip Belger, Mark Karcher, Helene Contemp Clin Trials Commun Article BACKGROUND: Exclusion criteria that are treatment effect modifiers (TEM) decrease RCTs results generalisability and the potentials of effectiveness estimation. In “augmented RCTs”, a small proportion of otherwise-excluded patients are included to allow for effectiveness estimation. In Hodgkin Lymphoma (HL) RCTs, older age and comorbidity are common exclusion criteria, while also TEM. We simulated HL RCTs augmented with age or comorbidity, and explored in each scenario the impact of augmentation on effectiveness estimation accuracy. METHODS: Simulated data with a population of HL individuals initiating drug A or B was generated. There were drug-age and drug-comorbidity interactions in the simulated data, with a greater magnitude of the former compared to the latter. Multiple augmented RCTs were simulated by randomly selecting patients with increasing proportions of older, or comorbid patients. Treatment effect size was expressed using the between-group Restricted Mean Survival Time (RMST) difference at 3 years. For each augmentation proportion, a model estimating the “real-world” treatment effect (effectiveness) was fitted and the estimation error measured (Root Mean Square Error, RMSE). RESULTS: In simulated RCTs including none (0%), or the real-world proportion (30%) of older patients, the interquartile range of RMST difference was 0.4–0.5 years and 0.2–0.3 years, respectively, and RMSE were 0.198 years (highest possible error) and 0.056 years (lowest), respectively. Augmenting RCTs with 5% older patients decreased estimation error substantially (RMSE = 0.076 years). Augmentation with comorbid patients proved less useful for effectiveness estimation. CONCLUSION: In augmented RCTs aiming to inform the effectiveness of drugs, augmentation should concern in priority those exclusion criteria of suspected important TEM magnitude, so as to minimie the proportion of augmentation necessary for good effectiveness estimations. Elsevier 2023-04-14 /pmc/articles/PMC10313858/ /pubmed/37397428 http://dx.doi.org/10.1016/j.conctc.2023.101142 Text en © 2023 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Nordon, Clementine
Sanchez, Benoit
Zhang, Mei
Wang, Xiaowei
Hunt, Phillip
Belger, Mark
Karcher, Helene
Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title_full Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title_fullStr Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title_full_unstemmed Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title_short Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
title_sort testing the “rct augmentation” methodology: a trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313858/
https://www.ncbi.nlm.nih.gov/pubmed/37397428
http://dx.doi.org/10.1016/j.conctc.2023.101142
work_keys_str_mv AT nordonclementine testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT sanchezbenoit testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT zhangmei testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT wangxiaowei testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT huntphillip testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT belgermark testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT karcherhelene testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness
AT testingtherctaugmentationmethodologyatrialsimulationstudytoguidethebroadeningoftrialseligibilitycriteriaandinformoneffectiveness